<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1751" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="967" end="977"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="1057" end="1067"/>
    <type:ORR xmi:id="21" sofa="6" begin="1290" end="1295"/>
    <type:ORR xmi:id="25" sofa="6" begin="1323" end="1328"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PURPOSE: Bevacizumab is an antibody that binds to vascular endothelial growth&#13;&#10;factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC).&#13;&#10;Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A&#13;&#10;prospective, randomized phase III trial of bevacizumab plus IFN versus IFN&#13;&#10;monotherapy was conducted.&#13;&#10;PATIENTS AND METHODS: Patients with previously untreated, metastatic clear-cell&#13;&#10;RCC were randomly assigned to receive either bevacizumab (10 mg/kg intravenously &#13;&#10;every 2 weeks) plus IFN (9 million U subcutaneously three times weekly) or the&#13;&#10;same dose and schedule of IFN monotherapy in a multicenter phase III trial. The&#13;&#10;primary end point was overall survival (OS). Secondary end points were&#13;&#10;progression-free survival (PFS), objective response rate (ORR), and safety.&#13;&#10;RESULTS: Between October 2003 and July 2005, 732 patients were enrolled. The&#13;&#10;prespecified stopping rule for OS has not yet been reached. The median PFS was&#13;&#10;8.5 months in patients receiving bevacizumab plus IFN (95% CI, 7.5 to 9.7 months)&#13;&#10;versus 5.2 months (95% CI, 3.1 to 5.6 months) in patients receiving IFN&#13;&#10;monotherapy (log-rank P &lt; .0001). The adjusted hazard ratio was 0.71 (95% CI,&#13;&#10;0.61 to 0.83; P &lt; .0001). Bevacizumab plus IFN had a higher ORR as compared with &#13;&#10;IFN (25.5% [95% CI, 20.9% to 30.6%] v 13.1% [95% CI, 9.5% to 17.3%]; P &lt; .0001). &#13;&#10;Overall toxicity was greater for bevacizumab plus IFN, including significantly&#13;&#10;more grade 3 hypertension (9% v 0%), anorexia (17% v 8%), fatigue (35% v 28%),&#13;&#10;and proteinuria (13% v 0%).&#13;&#10;CONCLUSION: Bevacizumab plus IFN produces a superior PFS and ORR in untreated&#13;&#10;patients with metastatic RCC as compared with IFN monotherapy. Toxicity is&#13;&#10;greater in the combination therapy arm."/>
    <cas:View sofa="6" members="1 13 17 21 25"/>
</xmi:XMI>
